Terminology Service for NFDI4Health
JSON

Rilimogene Galvacirepvec

Go to external page http://purl.obolibrary.org/obo/NCIT_C38681

A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA. [ ]

Term info

Label

Rilimogene Galvacirepvec

Synonyms
  • PROSTVAC
  • Prostvac-V
  • Recombinant Vaccinia-PSA(L155)-TRICOM Vaccine
  • Recombinant Vaccinia-PSA(L155)/TRICOM
  • Recombinant Vaccinia-PSA(L155)/TRICOM Vaccine
  • Rilimogene Galvacirepvec
  • rVaccinia-PSA(L155)-TRICOM Vaccine
  • rVaccinia-Prostate-Specific Antigen/TRICOM Vaccine
Subsets

NCIT_C116978, NCIT_C128784, NCIT_C116977, NCIT_C157711, NCIT_C157712

CAS Registry

1225283-43-1

Display Name

Rilimogene Galvacirepvec

Has Target

http://purl.obolibrary.org/obo/NCIT_C17525

Legacy Concept Name

Vaccinia-PSA-TRICOM_Vaccine

NSC Code

717170

Preferred Name

Rilimogene Galvacirepvec

Semantic Type

Pharmacologic Substance, Virus, Immunologic Factor

UMLS CUI

C1519903

code

C38681